Update on treatment of Hepatitis C: promising new molecules for difficult to treat patients
Atualizações no tratamento da Hepatite C: novas moléculas promissoras para pacientes de difícil tratamento
DOI:
https://doi.org/10.34117/bjdv8n11-028Keywords:
HCV, direct-acting antivirals, hepatocellular Carcinoma, Cirrhosis, hepatoprotective moleculesAbstract
Introduction: Hepatitis C is a disease triggered due to an infection by the hepatitis C virus and presents challenges in its treatment, even with the development of multiple direct-acting antivirals agents. Patients with hepatic decompensation or hepatocellular carcinoma and who have experienced treatment failures due to viral variants depend on the development of new molecules, that can be effective as antivirals or with other alternative properties that collaborate to improve symptoms and to avoid or mitigate clinical consequences. Objective: The aim of this review was to verify which new molecules were discovered and can be promising in face of the still persistent challenges in the treatment of hepatitis C. Method: A narrative review was carried out, searching for the specific keywords in PubMed and Google Scholar and molecules with greater potential to meet the demand of difficult to treat patients were selected. Result: The literature search showed that researchers have been engaged in the identification and discovery of new active compounds using various tools for rational drug design, making possible structural modifications that lead to improved effectiveness and pharmacological properties. Conclusion: Several molecules are in the process of being tested to meet the demands of difficult-to-treat patients, including molecules from natural products, and have the potential to help these patients.
References
Hepatitis C. Acesso em: 9 de janeiro, 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
Mesquita F, Santos ME, Benzaken A, Corrêa RG, Cattapan E, Sereno LS, et al. The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy. BMC Public Health 2016; (16): 1–6. Available from: /pmc/articles/PMC5094040/?report=abstract
Loader M, Moravek R, Witowski SE, Driscoll LM. A clinical review of viral hepatitis. J Am Acad Physician Assist. 2019; 32(11):15–20. Available from: https://pubmed.ncbi.nlm.nih.gov/31592934/
Meringer H, Shibolet O, Deutsch L. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm? World J Gastroenterol. 2019; 25(29):3929–40. Available from: /pmc/articles/PMC6689810/?report=abstract
Toshikuni N. Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis. Gut Liver 2017; 11(3):335–48. Available from: https://pubmed.ncbi.nlm.nih.gov/27840363/
Mücke MM, Mücke VT, Lange CM, Zeuzem S. Managing hepatitis C in patients with the complications of cirrhosis. Liver Int. 2018; 38:14–20. Available from: http://doi.wiley.com/10.1111/liv.13636
Huang H-C. Direct-acting antivirals. J Chinese Med Assoc. 2020; 83(4):319–20. Available from: http://journals.lww.com/10.1097/JCMA.0000000000000269
Velosa J. Why is viral eradication so important in patients with HCV-related cirrhosis? Antiviral Therapy. International Medical Press 2017; (22): 1–12. Available from: https://pubmed.ncbi.nlm.nih.gov/27553973/
Li H, Huang MH, Jiang JD, Peng ZG. Hepatitis C: From inflammatory pathogenesis to antiinflammatory/hepatoprotective therapy. World J. Gastroenterol. 2018; (24): 5297–311. Available from: https://pubmed.ncbi.nlm.nih.gov/30598575/
Zeuzem S. Treatment options in hepatitis C - The current state of the art. Dtsch Arztebl Int. 2017; 114(1–2):11–21. Available from: /pmc/articles/PMC5373481/?report=abstract
Tong L, Yu W, Chen L, Selyutin O, Dwyer MP, Nair AG, et al. Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms. J Med Chem. 2017; 60(1):290–306. Available from: https://pubmed.ncbi.nlm.nih.gov/27808515/
Asante-Appiah E, Liu R, Curry S, McMonagle P, Agrawal S, Carr D, et al. In vitro antiviral profile of ruzasvir, a potent and pangenotype inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother. 2018; 62(11). Available from: https://pubmed.ncbi.nlm.nih.gov/30150466/
Li X, Han J, Lee HW, Yoon YS, Jin Y, Khadka DB, et al. SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection. Bioorganic Med Chem. 2020; 28(19). Available from: https://doi.org/10.1016/j.bmc.2020.115679
Singal AG, Lim JK, Kanwal F. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. Clin. Liver Dis. 2020; (15):211–2. Available from: /pmc/articles/PMC7326632/?report=abstract
Pawlotsky JM. NS5A inhibitors in the treatment of hepatitis C. J. Hepatol. 2013; (59): 375–82. Available from: https://pubmed.ncbi.nlm.nih.gov/23567084/
Yang G, Wiles J, Patel D, Zhao Y, Fabrycki J, Weinheimer S, et al. Preclinical characteristics of ach-3102: a novel HCV ns5a inhibitor with improved potency against genotype-1a virus and variants resistant to 1st generation of ns5a inhibitors. J Hepatol. 2012; 56:S330. Available from: https://www.natap.org/2012/EASL/EASL_79.htm
Kanda T, Moriyama M. Odalasvir. Nonstructural protein 5A (NS5A) inhibitor, treatment of hepatitis C virus (HCV). Drugs Future. 2017; 42(9):549–53.
Sahuc M-E, Sahli R, Rivière C, Pène V, Lavie M, Vandeputte A, et al. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus , Is a New Inhibitor of Hepatitis C Virus RNA Replication . J Virol. 2019; 93(10):2009–27. Available from: http://jvi.asm.org/
Kwon JE, Lee YG, Kang JH, Bai YF, Jeong YJ, Baek NI, et al. Anti-viral activity of compounds from Agrimonia pilosa and Galla rhois extract mixture. Bioorg Chem. 2019; 93:103320. Available from: https://www.sciencedirect.com/science/article/pii/S0045206819305838#:~:text=Agrimonia%20pilosa%20(AP)%20and%20Galla,when%20two%20extracts%20are%20mixed.
Liu B, Gai K, Qin H, Wang J, Liu X, Cao Y, et al. Discovery of a Silicon-Containing Pan-Genotype Hepatitis C Virus NS5A Inhibitor. J Med Chem. 2020; 63(10):5312–23. Available from: https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.0c00082
Kazmierski WM, Baskaran S, Walker JT, Miriyala N, Meesala R, Beesu M, et al. GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage. J Med Chem. 2020; 63(8):4155–70. Available from: https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.9b02176
Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol. 1999; 6(10):937–43. Available from: http://structbio.nature.com
Xiao D, Dai X, Liu H, He S, Shi ZC, Ludmerer SW, et al. Multi-step parallel synthesis enabled optimization of benzofuran derivatives as pan-genotypic non-nucleoside inhibitors of HCV NS5B. Bioorganic Med Chem Lett. 2020; 30(7):127004. Available from: https://www.sciencedirect.com/science/article/pii/S0960894X20300688
Barreca ML, Iraci N, Manfroni G, Cecchetti V. Allosteric inhibition of the hepatitis C virus NS5B polymerase: In silico strategies for drug discovery and development. Future Med Chem. 2011; (3): 1027–55. Available from: https://www.future-science.com/doi/abs/10.4155/fmc.11.53
Mustafa G, Majid M, Ghaffar A, Yameen M, Samad HA, Mahrosh HS. Screening and molecular docking of selected phytochemicals against NS5B polymerase of hepatitis c virus. Pak J Pharm Sci. 2020; 33(5):2317–22. Available from: https://pubmed.ncbi.nlm.nih.gov/33832906/
Wang G, Dyatkina N, Prhavc M, Williams C, Serebryany V, Hu Y, et al. Synthesis and Anti-HCV Activities of 4′-Fluoro-2′-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4′-Fluoro-2′- C-methyluridine 5′-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection. J Med Chem. 2019; 62(9):4555–70. Available from: https://pubs.acs.org/sharingguidelines
Good SS, Moussa A, Zhou XJ, Pietropaolo K, Sommadossi JP. Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus. PLoS One. 2020; 15(1). Available from: https://pubmed.ncbi.nlm.nih.gov/31914458/
Khalid H, Landry KB, Ijaz B, Ashfaq UA, Ahmed M, Kanwal A, et al. Discovery of novel Hepatitis C virus inhibitor targeting multiple allosteric sites of NS5B polymerase. Infect Genet Evol. 2020; 1;84:104371. Available from: https://www.sciencedirect.com/science/article/pii/S1567134820302021
Wang G, Dyatkina N, Prhavc M, Williams C, Serebryany V, Hu Y, et al. Synthesis and Anti-HCV Activity of Sugar-Modified Guanosine Analogues: Discovery of AL-611 as an HCV NS5B Polymerase Inhibitor for the Treatment of Chronic Hepatitis C. J Med Chem. 2020; 63(18):10380–95. Available from: https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00935
Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function Nature 2005; (436):933–8. Available from: https://www.nature.com/articles/nature04077
Morikawa K, Lange CM, Gouttenoire J, Meylan E, Brass V, Penin F, et al. Nonstructural protein 3-4A: The Swiss army knife of hepatitis C virus. J. Viral Hepat. 2011; (18):305–15. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2893.2011.01451.x
Sun LQ, Mull E, D’Andrea S, Zheng B, Hiebert S, Gillis E, et al. Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection. J Med Chem. 2020; 63(23):14740–60. Available from: https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01296
Feld JJ, Foster GR. Second generation direct-acting antivirals – Do we expect major improvements? J. Hepatol. 2016; (65):130–42. Available from: https://pubmed.ncbi.nlm.nih.gov/27641983/
Abuelizz HA, Marzouk M, Bakheit Ac AH, Al-Salahi R. Investigation of some benzoquinazoline and quinazoline derivatives as novel inhibitors of HCV-NS3/4A protease: biological, molecular docking and QSAR studies. RSC Adv. 2020; (10): 35820-35830. Available from: https://pubs.rsc.org/en/content/articlelanding/2020/ra/d0ra05604a
Wei Y, Yang J, Kishore Sakharkar M, Wang X, Liu Q, Du J, Zhang JJ. Evaluating the inhibitory effect of eight compounds from Daphne papyracea against the NS3/4A protease of hepatitis C virus. Nat Prod Res. 2020; 34(11):1607–10. Available from: https://pubmed.ncbi.nlm.nih.gov/30449158/
Shady NH, Khattab AR, Ahmed S, Liu M, Quinn RJ, Fouad MA, et al. Hepatitis c virus ns3 protease and helicase inhibitors from red sea sponge (Amphimedon) species in green synthesized silver nanoparticles assisted by in silico modeling and metabolic profiling. Int J Nanomedicine 2020; 15:3377–89. Available from: /pmc/articles/PMC7231760/?report=abstract
Uma Reddy B, Tandon H, Pradhan MK, Adhikesavan H, Srinivasan N, Das S, et al. Potent HCV NS3 Protease Inhibition by a Water-Soluble Phyllanthin Congener. ACS Omega 2020; 5(20):11553–62. Available from: https://dx.doi.org/10.1021/acsomega.0c00786
Lim SK, Othman R, Yusof R, Heh CH. Rational drug discovery: Ellagic acid as a potent dual-target inhibitor against hepatitis C virus genotype 3 (HCV G3) NS3 enzymes. Chem Biol Drug Des 2021; 97(1):28–40. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/cbdd.13756
Widyawaruyanti A, Tanjung M, Permanasari AA, Saputri R, Tumewu L, Adianti M, et al. Alkaloid and benzopyran compounds of Melicope latifolia fruit exhibit anti-hepatitis C virus activities. BMC Complement Med Ther 2021; 21(1):27. Available from: https://bmccomplementalternmed.biomedcentral.com/articles/10.1186/s12906-021-03202-8
Youngberg S, Brandt E, Barve A, Machineni S, Jones CT, Dabovic K, et al. A first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending oral dose study to assess the safety, tolerability, and pharmacokinetics of BZF961 with and without ritonavir in healthy adult volunteers. J Drug Assess 2018; 7(1):66–74. Available from: https://www.tandfonline.com/action/journalInformation?journalCode=ijda20
Lawitz E, Bidair M, Marbury T, Jones CT, Barve A, Magnusson B, et al. The Safety and Antiviral Activity of BZF961 with or without Ritonavir in Patients Infected with Hepatitis C Virus: A Randomized, Multicenter Trial. Clin Ther. 2018; 40(9):1567-1581. Available from: https://doi.org/10.1016/j.clinthera.2018.07.019
Li B, Li L, Peng Z, Liu D, Si L, Wang J, Yuan B, Huang J, Proksch P, Lin W. Harzianoic acids A and B, new natural scaffolds with inhibitory effects against hepatitis C virus. Bioorg Med Chem 2019; 27(3):560–7. Available from: https://pubmed.ncbi.nlm.nih.gov/30606673/
Kaul A, Stauffer S, Berger C, Pertel T, Schmitt J, Kallis S, et al. Essential Role of Cyclophilin A for Hepatitis C Virus Replication and Virus Production and Possible Link to Polyprotein Cleavage Kinetics. PLoS Pathog 2009; 5(8):e1000546. Available from: https://dx.plos.org/10.1371/journal.ppat.1000546
Shimizu JF, Lima CS, Pereira CMH, Bittar C, Batista MN, Nazaré AC, et al. Flavonoids from Pterogyne nitens Inhibit Hepatitis C Virus Entry. Sci Rep 2017; 7(1):1–9. Available from: www.nature.com/scientificreports
Wu Y, Wang F, Zheng Q, Lu L, Yao H, Zhou C, et al. Hepatoprotective effect of total flavonoids from Laggera alata against carbon tetrachloride-induced injury in primary cultured neonatal rat hepatocytes and in rats with hepatic damage. J Biomed Sci 2006; 13(4):569–78. Available from: https://pubmed.ncbi.nlm.nih.gov/16547767/
Wan L, Jiang JG. Protective effects of plant-derived flavonoids on hepatic injury. J. Funct. Foods 2018; (44):283–91. Available from: https://www.sciencedirect.com/science/article/pii/S1756464618301014#:~:text=Some%20of%20flavonoids%20have%20remarkable,a%20variety%20of%20liver%20injuries.&text=Enzyme%20activity%2C%20inflammatory%20cytokines%2C%20and,are%20their%20main%20regulatory%20targets.&text=Identification%20of%20flavonoids%20with%20liver,for%20developing%20new%20liver%20aids.
Buonomo AR, Scotto R, Nappa S, Arcopinto M, Salzano A, Marra AM, et al. The role of curcumin in liver diseases. Arch Med Sci 2019; (15):1608–20. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855174/
Sharma OP. Antioxidant activity of curcumin and related compounds. Biochem Pharmacol 1976; 25(15):1811–2. Available from: https://pubmed.ncbi.nlm.nih.gov/942483/
Ralhan R, Pandey MK, Aggarwal BB. Nuclear factor-kappa B links carcinogenic and chemopreventive agents. Front Biosci 2009; (1):45–60. Available from: https://pubmed.ncbi.nlm.nih.gov/19482682/
